Longitudinal evaluation of serum MOG-IgG titers in MOGAD after initiation of maintenance immunoglobulin: A case series

Authors

Shuvro Roy, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Eleni Vasileiou, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Paula Barreras, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Gelareh Ahmadi, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Haiwen Chen, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
William Suslovic, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Alexandra Kornbluh, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Ilana Kahn, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Elias S. Sotirchos, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.

Document Type

Journal Article

Publication Date

11-29-2023

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)

DOI

10.1177/13524585231211119

Keywords

Biomarkers; IVIg; MOGAD; disease-modifying therapies

Abstract

BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system. Immunoglobulin (Ig) has been used as a maintenance therapy to prevent relapses in MOGAD, but the impact of Ig on serum MOG-IgG titers is unclear. OBJECTIVE: To characterize the variation in serum MOG-IgG titers after initiation of Ig treatment in people with MOGAD. METHODS: We conducted a retrospective study of 10 patients with a diagnosis of MOGAD and available serum MOG-IgG titers before and after initiation of maintenance Ig treatment. RESULTS: We found that most of the patients remained MOG-IgG seropositive while on Ig treatment with a reduced or unchanged titer, despite a lack of disease activity. CONCLUSIONS: This case series suggests that the mechanism of action of Ig therapy in MOGAD is not exclusively dependent on MOG-IgG titer reduction.

APA Citation

Roy, Shuvro; Vasileiou, Eleni; Barreras, Paula; Ahmadi, Gelareh; Chen, Haiwen; Suslovic, William; Kornbluh, Alexandra; Kahn, Ilana; and Sotirchos, Elias S., "Longitudinal evaluation of serum MOG-IgG titers in MOGAD after initiation of maintenance immunoglobulin: A case series" (2023). GW Authored Works. Paper 3752.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/3752

Department

Neurology